Summary of Sanli Pharmaceutical Conference Call Company Overview - **Company**: Sanli Pharmaceutical - **Core Products**: Kaohoujian series, particularly the pediatric version with over 80% coverage in secondary hospitals [2][4] Industry Insights - **Market Focus**: The company aims to enhance coverage in grassroots medical institutions, which could significantly boost sales if products are included in the essential drug list [2][4] - **OTC Business Development**: Sanli is focusing on developing its OTC business, segmented into respiratory and elderly care lines to meet market demands [2][6] Financial Projections - **2026 Revenue Forecast**: Expected total revenue of approximately 1.9 to 2 billion CNY, with contributions from: - Respiratory line: 1.2 to 1.3 billion CNY - Supplement line: 400 to 500 million CNY - Other product lines: 100 to 200 million CNY - **2025 Performance Outlook**: Anticipated revenue of 1.6 to 1.7 billion CNY due to low incidence of respiratory diseases and inventory pressure [3][21] Product Pipeline and R&D - **Essential Drug List Candidates**: Four products are potential candidates for the essential drug list, with the pediatric Kaohoujian having the highest probability of inclusion [4][13] - **Innovation Strategy**: The company has shifted focus from classic formulas to innovative traditional Chinese medicine, collaborating with research institutions on multiple projects expected to yield results in six to eight years [11][24] Market Strategy - **Sales Channel Expansion**: Sanli has transitioned from prescription sales to a multi-channel sales approach, including partnerships with top national chains and an emphasis on O2O (online-to-offline) retail strategies [6][18] - **Grassroots Market Potential**: The company aims to increase its market share in grassroots settings, currently at 5% to 8%, with a target of 20% to 30% for successful products [15] Competitive Landscape - **Impact of Drug List Adjustments**: Inclusion in the essential drug list could significantly enhance market penetration and prescription volumes for key products [12][14] - **Response to Price Reductions**: The company does not view price reductions from centralized procurement as detrimental, as it can reduce sales expenses to maintain profit margins [17] Operational Readiness - **Capacity and Distribution**: Preparations for the new essential drug list have been ongoing since 2018, focusing on channel development and distribution team enhancements [16] - **Integration of Acquisitions**: The integration of acquired companies is nearly complete, with a unified sales strategy across the OTC business [22] Challenges and Risks - **Inventory Management**: The company has faced inventory pressures due to low disease incidence, impacting financial performance in 2025 [20] - **Market Competition**: The company acknowledges the competitive landscape in the orthopedic and gynecological sectors, which are not yet significant revenue contributors [7] Conclusion Sanli Pharmaceutical is strategically positioned to enhance its market presence through innovative product development, expansion into grassroots healthcare, and a robust OTC strategy. The potential inclusion of key products in the essential drug list could further drive growth, despite current challenges related to inventory and market competition.

Core Viewpoint - The company expects a net profit attributable to shareholders of 15 million to 16 million yuan for the full year of 2025, driven by growth in the OTC hearing aid market and successful integration of acquired technology [1] Group 1: Performance Forecast - The company anticipates a year-on-year increase in net profit attributable to shareholders for 2025, primarily due to sustained demand in the U.S. OTC market and enhanced operational strategies [1] - The company has strengthened partnerships with key brand clients, leading to increased orders and revenue from brand partners [1] - The company has accelerated the development of its own brand channels, resulting in significant revenue growth from proprietary products [1] Group 2: Recent Financial Results - For the first three quarters of 2025, the company reported a main operating revenue of 196 million yuan, an increase of 82.44% year-on-year [2] - The net profit attributable to shareholders for the same period reached approximately 17.63 million yuan, reflecting a year-on-year increase of 565.54% [2] - The third quarter alone saw a main operating revenue of 82.22 million yuan, up 87.17% year-on-year, with a net profit of approximately 991.96 thousand yuan, marking a staggering increase of 1162.04% [2]

Core Viewpoint - The recent delisting of SPACs associated with Chinese companies has halted their plans for U.S. listings, highlighting the risks of the SPAC model and the unique value of the OTC market [1] Group 1: SPAC Delisting and Its Implications - Nasdaq delisted 13 securities on January 13, including three SPACs (Four Leaf, DT Cloud, AlphaTime) linked to Chinese companies, transferring them to the OTC market [1] - The delisting exposes the vulnerabilities of the SPAC model, particularly the reliance on the SPAC's continued listing status [4] - The case of Xiaoyu Tidata illustrates that even with stable business operations, a SPAC's delisting can abruptly halt the entire listing process [4] Group 2: Regulatory Changes and Challenges - New Nasdaq regulations effective January 17, 2026, will raise the minimum public float market value requirement from $5 million to $15 million and mandate that SPAC mergers must raise at least $25 million in public funds [4] - These regulatory changes create significant barriers for many small and medium-sized enterprises [4] Group 3: Advantages of the OTC Market - The OTC market offers a crucial buffer, allowing SPACs to continue merger transactions even after delisting from the main board [5] - OTC has lower financial requirements, with no strict profitability criteria and minimal annual fees ranging from a few thousand to $20,000 [6] - The listing process on the OTC market can be completed in 3-6 months, significantly faster than the 12-24 months required for a Nasdaq IPO [7] Group 4: Structured Compliance and Growth Opportunities - The OTC market features a four-tier compliance structure, catering to different stages of company development [8] - Companies already listed on domestic boards can issue ADRs on OTCQX without meeting stringent SEC registration requirements, facilitating exposure to U.S. investors [9] - The OTC market serves as a "golden stepping stone" for companies aiming to transition to Nasdaq or NYSE, with approximately 15% of Nasdaq-listed companies having previously grown on the OTC market [10] Group 5: Diverse Financing Options - The OTC market supports various financing methods, including private placements and convertible bonds, which are particularly suitable for light-asset companies in technology and biomedicine [11] - Companies can leverage the OTC market to access global financing while providing liquidity options for early investors [11] - The current delisting trend reinforces the need for Chinese companies to consider paths beyond the main board for U.S. listings [11]

Core Viewpoint - The listing plans of Chinese company Xiaoyu Dida in the U.S. have changed due to its partner SPAC, Four Leaf Acquisition Corp, being delisted from Nasdaq and moving to OTC trading, alongside three other SPACs involving Chinese companies facing similar situations [1] Group 1: Regulatory Changes - Nasdaq's new regulations effective January 17, 2026, significantly raise the listing thresholds for SPACs, contributing to a cautious attitude from capital towards Chinese SPAC projects [1] Group 2: Market Trends - The financing scale for Chinese companies listing in the U.S. has decreased by 41% year-on-year as of mid-2025, further exacerbating the cautious approach from investors [1] Group 3: OTC Market Opportunities - The OTC market is emerging as a new option for cross-border financing for Chinese companies due to its lower thresholds, reduced costs, simplified approval processes, and more lenient information disclosure requirements [1] - Institutions like Edenhall Global Capital are assisting Chinese companies in achieving cross-border capital operations through the OTC market [1]

Group 1 - The core viewpoint of the article highlights the increasing challenges for Chinese companies to list on the US main board due to new regulations from major exchanges, leading to a renewed interest in the OTC Markets as a viable alternative for cross-border financing [1][8] Group 2 - Nasdaq's new regulations include a significant increase in financial thresholds for IPOs, with net income requirements rising from $5 million to $15 million (200% increase) and revenue listing standards from $8 million to $15 million (87.5% increase), resulting in only 12% of Chinese companies expected to meet these criteria for 2024 [2] - Additional restrictions for companies primarily operating in China include a minimum fundraising threshold of $25 million, with the potential for denial of listing based on perceived risks, even if formal compliance is met [2] Group 3 - The NYSE has also raised its IPO revenue requirement to $15 million and increased the minimum stock price to $4, while extending the IPO review period from 12-24 months due to enhanced scrutiny on VIE structures and data security [3] Group 4 - Data from 2025 shows that among 93 Chinese companies listed on the US main board, only one transitioned from OTC, with nearly 70% of IPO companies raising less than $10 million, contrasting sharply with the new $25 million fundraising threshold [4] Group 5 - The OTC market presents a pragmatic choice for Chinese companies seeking cross-border financing, with lower entry barriers and a tiered system that accommodates various stages of business development [5] - The OTCQX and OTCQB have significantly lower annual fees compared to Nasdaq, with OTCQX costing $25,000-$30,000 and OTCQB around $15,000, while the Pink Limited tier has no mandatory profit or audit requirements [6] Group 6 - Transitioning from OTC to Nasdaq or NYSE is streamlined, with clear criteria for companies to apply for transfer and an average review period of 6-8 weeks, showing a high success rate for those moving to Nasdaq [7] Group 7 - The 2026 cross-border financing policies in China, combined with the OTC market's advantages, are expected to facilitate easier capital flow and reduce compliance risks for Chinese companies [7] - International investment banks predict that the US IPO market will see significant activity in the coming year, with a financing scale projected between $40 billion and $60 billion, primarily driven by large unicorns, while smaller companies continue to face liquidity challenges [8]

Core Viewpoint - The OTC market is emerging as a viable alternative for Chinese companies seeking to list in the U.S., offering more flexible listing conditions compared to traditional exchanges like NASDAQ and NYSE. Group 1: Financial Conditions - The OTC market has no strict profitability requirements, allowing companies in R&D or market expansion phases to attract early investors based on their innovative potential and technological advantages [1] - NASDAQ requires a minimum cumulative pre-tax income of $11 million over the last three years and at least $2.2 million in the last two years, which poses a significant barrier for many high R&D investment companies [1] Group 2: Market Capitalization and Cash Flow - NASDAQ typically mandates a minimum market capitalization of $75 million and certain cash flow standards, while the OTC market does not impose uniform hard requirements, thus providing access for smaller companies with unstable cash flows but growth potential [2] Group 3: Share Structure and Shareholder Distribution - The OTC market has lower public shareholding and shareholder number requirements compared to NASDAQ, which requires a public market value of at least $125 million and at least 400 shareholders holding over 100 shares [4] - This flexibility allows companies to focus more on business development without excessive early-stage equity dilution [4] Group 4: Compliance and Information Disclosure - The OTC market offers a simplified disclosure process, reducing compliance costs and allowing companies to allocate more resources to operations and development, in contrast to NASDAQ's strict and complex disclosure requirements [7] Group 5: Corporate Governance - The OTC market provides more transitional space for corporate governance, allowing companies to gradually improve their governance structures, unlike NASDAQ, which has specific requirements for independent board members and committee setups [8] Group 6: Summary of OTC's Position and Value - Overall, the OTC market is more inclusive in terms of profitability thresholds, market capitalization requirements, share flexibility, and compliance costs compared to traditional exchanges [10] - For Chinese companies, the OTC market serves as a flexible international capital starting point, a bridge connecting early-stage companies with global funding, and a strategic channel for growth, transition, and sustainable expansion [10]

Core Viewpoint - The regulatory framework of the US and China capital markets is continuously adjusting, creating both opportunities and challenges for Chinese companies seeking cross-border financing. The increasing entry barriers for traditional IPOs and the evolving SPAC landscape are pushing smaller enterprises towards the OTC market as a pragmatic entry point into international capital markets [1]. Group 1: Direct IPO (NYSE/NASDAQ) - The traditional IPO route offers significant advantages such as large fundraising potential (with a proposed minimum of $25 million), strong liquidity, and notable brand endorsement, making it suitable for mature tech or manufacturing firms [2]. - However, the disadvantages are considerable, including a lengthy SEC review process of 12-24 months, underwriting fees of 7%-10% of the raised amount, and stringent financial criteria, particularly with the anticipated increase in market capitalization requirements by NASDAQ [2]. - Post-2025, while the resumption of filing windows is expected, compliance issues related to VIE structures and data security reviews remain significant obstacles [2]. Group 2: SPAC Merger Listing - The SPAC model allows for rapid listing through a "shell company fundraising - merger injection" approach, reducing the timeline to 6-9 months and imposing no strict profitability requirements [3]. - Nonetheless, with tightening regulations expected in 2025, SPACs face challenges such as high redemption rates (averaging over 97%) and rising PIPE financing costs (5%-7% of the raised amount), making it more suitable for companies in AI and renewable energy sectors that can effectively communicate their value [3]. Group 3: OTC Market Listing - The OTC market represents the lowest entry barrier, characterized by its "stepping stone" attribute, making it an optimal choice for small and medium-sized enterprises [4]. - For example, the OTCQB listing process typically spans 6-9 months, involving foundational setup (2-3 weeks), issuance and listing (3-6 weeks), requiring 50-100 shareholders and a minimum share price of $1 [5]. - Companies can transition to NASDAQ by meeting specific criteria, such as net assets of at least $5 million or a two-year cumulative net profit of $750,000 alongside net assets of $4 million, with additional requirements including 1 million shares in circulation and a share price of at least $4 [6]. Group 4: Compliance Preparation - The compliance preparation phase for OTC listing takes approximately 4-5 weeks, involving DTC custody applications and drafting the S-1 prospectus [7]. - Following this, the SEC review process lasts about 4 weeks, during which the application is submitted, inquiries are addressed, and a stock code is obtained [7].

Core Viewpoint - The OTC market serves as a vital platform for small and medium-sized enterprises (SMEs) to access financing and transition to larger exchanges like NASDAQ and NYSE, acting as a "fast track" for companies aiming for higher market visibility and capital access [2]. PART.1: Current Status of OTC Markets - Since 2007, OTC Markets Group has restructured the OTC market into four tiers: OTCQX, OTCQB, OTC ID, and Pink Limited, enhancing the organization and transparency of the market [4]. PART.2: Financing Methods for Chinese Enterprises in the OTC Market - OTC market listings can facilitate financing, similar to China's New Third Board, although the extent of financing depends on the enterprise's value [10]. - Pre-listing equity financing is crucial for companies before they list on the OTC market, with underwriters playing a key role in developing effective equity plans [11]. - Companies listed in the OTC ID and Pink markets can raise funds through the issuance of new shares, leveraging their OTC status to attract domestic investors [12]. - Effective market capitalization management can enhance investor confidence and drive stock price appreciation, facilitating further fundraising opportunities [13]. PART.3: Trading Mechanisms in the OTC Market - The trading process in the OTC market is similar to that of U.S. stock exchanges, with prices reflecting market supply and demand [15]. - The OTC market operates on a dealer network system, where market makers provide liquidity by continuously buying and selling securities [16]. - Transactions are conducted through brokers, allowing for negotiation between parties to achieve optimal trading outcomes [17]. PART.4: Retail Shareholders and OTC Shell Companies - Domestic retail shareholders can register as shareholders of OTC shell companies, as there is no limit on the number of shareholders, allowing for free trading in the secondary market [18].

Core Mechanism - The OTC market operates without a central trading hall and relies on market maker quotes [10] - Market makers are essential to the OTC trading process, holding inventory and providing buy and sell quotes [10] Trading Process - Investors place buy or sell orders for OTC stocks through their brokerage accounts [2] - If the brokerage has a market-making department, it may attempt to internally match client buy and sell orders [2] - Orders are typically routed to market makers or accessed through the OTC Link ECN [2][7] - The transaction price is determined by the market maker's quoted price, not the investor's limit price unless the limit is better than the market maker's quote [4] Electronic Platform - OTC Link ATS is the core electronic trading platform operated by OTC Markets Group, connecting hundreds of market makers and brokerages [5] - Market makers update their quotes in real-time through OTC Link [6] Important Characteristics - OTC stocks tend to have higher price volatility due to lower liquidity and potentially insufficient company information [8] - Trading hours align with major exchanges, operating from 9:30 AM to 4:00 PM Eastern Time, with possible pre-market and after-hours trading [9] - The settlement cycle is consistent with the U.S. stock market standard of T+2 [9] Investor Steps - Investors must choose a brokerage capable of OTC trading and complete account registration [11] - Funds can be deposited into the trading account via bank cards or third-party payment methods [11]